<DOC>
	<DOCNO>NCT02700841</DOCNO>
	<brief_summary>This pilot , randomize phase II trial study well deplete immune suppressor stem cell transplant work compare standard stem cell transplant enhance immune response vaccine patient multiple myeloma ( MM ) . Chemotherapy patient 's stem cell effective treat MM , however risk disease return due poor recovery immune system show poor response vaccine prevent infection . Before chemotherapy , patient ' stem cell collect certain immune cell call suppressor cell remove stem cell . Patients receive chemotherapy kill cancer cell immune depleted stem cell return replace blood-forming cell destroy chemotherapy . Giving deplete immune suppressor stem cell transplant patient MM may result robust immune response vaccine transplant may prevent MM return . It yet know whether deplete immune suppressor stem cell transplant effective standard stem cell transplant enhance immune response vaccine patient multiple myeloma .</brief_summary>
	<brief_title>Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare cellular humoral vaccine response post-transplant two arm . II . To determine feasibility safety approach . SECONDARY OBJECTIVES : I . To compare post-transplant recovery innate adaptive immune cell ( cluster differentiation [ CD ] CD8 , CD4 , CD19 , natural killer cell [ NK ] , gamma delta T-cells ) , addition T-cell phenotype marker two arm . II . To compare post-transplant recovery regulatory T-cells ( T-regs ) myeloid derive suppressor cell ( MDSCs ) two arm . III . Progression free survival 2 year post-transplant . IV . To compare multiple myeloma ( MM ) minimal residual disease ( MRD ) status 3 month post-transplant two arm . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive X box bind protein-1 ( XBP1 ) -US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 subcutaneously ( SC ) every 2 week 3 dos transplant day 1 , 15 , 30 tetanus influenza vaccine intramuscularly ( IM ) 3rd dose vaccine dose transplant . Patients receive condition regimen comprise high-dose melphalan intravenously ( IV ) day -2 undergo autologous CD34 hematopoietic stem cell transplant ( HSCT ) day 0 . Patients also receive autologous donor lymphocyte ( DLI ) IV day 2 . ARM II : Patients receive XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 subcutaneously tetanus influenza vaccine Arm I . Patients receive high-dose melphalan IV day -2 undergo autologous hematopoietic stem cell transplant ( AHSCT ) day 0 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<criteria>Diagnosis multiple myeloma The first 3 patient experimental arm high risk myeloma subsequent patient low risk myeloma . High risk multiple myeloma patient : Have deletion ( del ) 17p , del 1p , T ( 4 ; 14 ) , T ( 14 ; 16 ) Have plasma cell leukemia ( PCL ) Have &gt; 1 cytogenetic abnormality Are hypodiploid Have fail adequate initial therapy ( lenalidomide , bortezomib , dexamethasone [ RVD ] , thalidomide , bortezomib , dexamethasone [ TVD ] , cyclophosphamide , bortezomib , dexamethasone [ CyBorD ] ) Have plan receive nonchemotherapy/cytotoxic salvage regimen ( except single agent cyclophosphamide ) . Able understand sign consent form Creatinine clearance equal &gt; 50 ml/min ( calculate ) Ejection fraction equal &gt; 50 % admission transplant per institutional standard . Patients coronary heart disease ( recent myocardial infarction , angina , cardiac stent , bypass surgery last 6 month arrhythmia ) need clear cardiology per Emory bone marrow transplant ( BMT ) standard . Serum bilirubin , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less 3 X upper limit normal Forced vital capacity ( FVC ) , forced expiratory volume one second ( FEV1 ) diffusion capacity carbon monoxide ( DLCO ) &gt; 50 % predicted admission transplant per institutional standard . Patients home oxygen allow protocol . No six month ' worth multiple myeloma chemotherapy allow ( date start induction therapy ) Karnofsky performance status ( KPS ) ≥ 70 % Patients must eligible receive melphalan dose 200 mg/m² Patients must human leukocyte antigen ( HLA ) A2 positive polymerase chain reaction ( PCR ) type A female childbearing potential , must two negative urine pregnancy test result within 10 14 day prior start first dose vaccine lenalidomide pretransplant Patient prior stem cell transplant ( autologous allogeneic ) Creatinine clearance &lt; 50 ml/min ( calculate ) Patients documented central nervous system ( CNS ) disease Significant organ dysfunction deem inappropriate autologous transplantation Intention plan cyclophosphamide mobilization Patients active hepatitis B , C human immunodeficiency virus ( HIV ) infection ( PCR positive ) Enrollment transplant related protocol Pregnant woman exclude participate study ; collect urine pregnancy test female patient postmenopausal surgically sterile part standard care . If positive , repeat confirm result prior visit 2 ; second positive test result exclusion patient study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>